Statin-fibrate combinations in patients with combined hyperlipedemia.
Athyros
V G
VG
Papageorgiou
A A
AA
Kontopoulos
A G
AG
D002995:Clofibric Acid / Q000008:administration & dosage / Q000031:analogs & derivatives; D003327:Coronary Disease / Q000401:mortality; D004359:Drug Therapy, Combination; D058607:Fibric Acids; D005500:Follow-Up Studies; D015248:Gemfibrozil / Q000008:administration & dosage*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D006950:Hyperlipidemia, Familial Combined / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006954:Hyperlipoproteinemia Type V / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000008:administration & dosage*; D009203:Myocardial Infarction / Q000150:complications; D017035:Pravastatin / Q000008:administration & dosage; D019821:Simvastatin / Q000008:administration & dosage*; D020521:Stroke / Q000401:mortality
D058607:Fibric Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D002995:Clofibric Acid; D019821:Simvastatin; C019304:ciprofibrate; D017035:Pravastatin; D015248:Gemfibrozil